Cardiac surveillance for anti-HER2 chemotherapy

ABSTRACT

Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.

KEY POINTS

Accurate diagnosis of cardiotoxicity is critical, as false-positive results may lead to inappropriate stopping of potentially lifesaving chemotherapy.

We suggest routine serial measurement of left ventricular ejection fraction by echocardiography only for patients who have received anthracyclines or are considered at high cardiac risk.

All patients should be counseled to promptly report relevant symptoms.

For patients who develop clinically significant congestive heart failure, discontinuing anti-HER2 therapy should be strongly considered.

doi:10.3949/ccjm.88a.19150

ANTI-HUMAN EPIDERMAL GROWTH FACTOR receptor 2 (anti-HER2) therapy has been a game-changer for some forms of aggressive breast cancer, drastically reducing mortality rates. The US Food and Drug Administration (FDA) calls for close cardiac surveillance in patients receiving these drugs. But this recommendation is based on an early clinical trial with circumstances that are no longer frequently relevant. As it now stands, this strategy is burdensome, dangerous for patients who are unnecessarily advised to discontinue therapy, and often ignored in practice.

This article discusses what drove the current FDA cardiac surveillance strategy for anti-HER2 therapy and the challenges it poses in practice and clinical research. Results of more recent clinical trials are reviewed, and in light of them, new best practices for anti-HER2 therapy management and cardiac monitoring are proposed.
breast cancer mortality rates, in what is widely regarded as a phenomenal success story. Anti-HER2 agents include the following:

**Monoclonal antibodies**, eg, trastuzumab, which targets the extracellular domain of HER2, and pertuzumab, which prevents HER2 receptor homodimerization and heterodimerization, which are necessary for activation.

**Ado-trastuzumab emtansine**, an antibody-drug conjugate.

**Small-molecule inhibitors** that block the HER2 receptor intracellularly, eg, lapatinib, available in oral formulations.

Other targeted anti-HER2 therapies are continually being developed.

### CARDIAC ISSUES WITH TRASTUZUMAB DISCOVERED EARLY

Current FDA recommendations regarding the frequency of surveillance of left ventricular function with anti-HER2 therapy are conservatively based on historical data involving patients receiving concomitant anthracycline therapy.

The pivotal trastuzumab randomized controlled trial in patients with metastatic breast cancer, published in 2001, reported a 27% rate of cardiac dysfunction and a 16% rate of New York Heart Association (NYHA) class III or IV heart failure in patients who received trastuzumab with anthracycline chemotherapy. These findings prompted the FDA to issue a stern package-insert warning of cardiomyopathy for anti-HER2 treatments, and recommendations for cardiac surveillance.

Trastuzumab’s package insert recommends measuring left ventricular ejection fraction (LVEF) before starting therapy, every 3 months during treatment, and at the completion of therapy. If drug therapy is withheld for cardiotoxicity, studies should be repeated.

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>No. of patients</th>
<th>Duration (years)</th>
<th>Early vs metastatic</th>
<th>Anthracycline</th>
<th>Follow-up (years)</th>
<th>Echo-cardiography result</th>
<th>LVEF drop (%)</th>
<th>Heart failure incidence (%)</th>
<th>Cardiac death (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OHERA</td>
<td>2019</td>
<td>3,733</td>
<td>1</td>
<td>Early</td>
<td>Yes</td>
<td>5</td>
<td>4+</td>
<td>2</td>
<td>3</td>
<td>&lt;1</td>
</tr>
<tr>
<td>KATHERINE</td>
<td>2019</td>
<td>1,486</td>
<td>0.4</td>
<td>Early</td>
<td>No</td>
<td>5</td>
<td>4+</td>
<td>NA</td>
<td>NA</td>
<td>0</td>
</tr>
<tr>
<td>NSABP</td>
<td>2017</td>
<td>407</td>
<td>1</td>
<td>Early</td>
<td>Yes</td>
<td>5</td>
<td>4+</td>
<td>1</td>
<td>NA</td>
<td>&lt;1</td>
</tr>
<tr>
<td>HERA</td>
<td>2017</td>
<td>5,099</td>
<td>1–2</td>
<td>Early</td>
<td>No</td>
<td>10</td>
<td>4+</td>
<td>&lt;1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>APHINITY</td>
<td>2017</td>
<td>4,805</td>
<td>1</td>
<td>Early</td>
<td>No</td>
<td>10</td>
<td>4+</td>
<td>NA</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Dang et al</td>
<td>2016</td>
<td>406</td>
<td>1</td>
<td>Both</td>
<td>No</td>
<td>4</td>
<td>4+</td>
<td>NA</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>HORG</td>
<td>2015</td>
<td>481</td>
<td>1</td>
<td>Early</td>
<td>No</td>
<td>7</td>
<td>3+</td>
<td>&lt;1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CLEOPATRA</td>
<td>2013</td>
<td>804</td>
<td>1</td>
<td>Both</td>
<td>No</td>
<td>3</td>
<td>3+</td>
<td>1</td>
<td>1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>NeoSphere</td>
<td>2012</td>
<td>417</td>
<td>0.4</td>
<td>Both</td>
<td>No</td>
<td>2 weeks</td>
<td>3+</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>BCIRG-006</td>
<td>2011</td>
<td>3,222</td>
<td>1</td>
<td>Both</td>
<td>Yes</td>
<td>5</td>
<td>7+</td>
<td>14</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Slamon et al</td>
<td>2001</td>
<td>234</td>
<td>0.8</td>
<td>Metastatic</td>
<td>Yes</td>
<td>&gt;2</td>
<td>NA</td>
<td>16</td>
<td>27</td>
<td>0</td>
</tr>
</tbody>
</table>

* All trials included radiation therapy and were adjudicated.
* Pivotal trial leading to stringent US Food and Drug Administration recommendations for cardiac surveillance.

**APHINITY** = A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer; **BCIRG** = Breast Cancer International Research Group; **CLEOPATRA** = A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer; **HER2** = human epidermal growth factor receptor 2; **HERA** = HERceptin Adjuvant; **HORG** = Hellenic Oncology Research Group; **KATHERINE** = A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy; **LVEF** = left ventricular ejection fraction; **NA** = not available; **NeoSphere** = A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer; **NSABP** = National Surgical Adjuvant Breast and Bowel Project; **OHERA** = Observational Study of Cardiac Events in Patients With HER2-Positive EBC Treated with Herceptin.
ANTI-HER2 CHEMOTHERAPY CARDIAC SURVEILLANCE

monthly. Furthermore, after completion of therapy, LVEF should be measured every 6 months for at least 2 years. Thus, a minimum of 9 echocardiograms is recommended for patients undergoing a standard 12-month adjuvant dosing schedule, with an indefinite (and potentially lifelong) number of 3-monthly echocardiograms for those with metastatic disease on continual anti-HER2 therapy.

■ RECENT DATA PUT RECOMMENDATIONS IN QUESTION

Subsequent clinical trials7–16 have generally indicated a more favorable cardiac profile (Table 1). The 2007 Herceptin Adjuvant (HERA) trial found a 3% rate of cardiac dysfunction and a 0.6% rate of NYHA III or IV heart failure.17 A 2019 trial8 found that only 1.2% of patients discontinued dual therapy because of decreased ejection fraction, while adjudicated cardiac events occurred in less than 1%. The relationship between decreased ejection fraction assessed by cardiac monitoring and the development of clinical heart failure was not discussed.

Although the risk of cardiac dysfunction from anti-HER2 therapy now appears low, the FDA package-insert warning and recommendations remain. Extensive cardiac monitoring and echocardiographic testing regimens are still part of the standard protocols of clinical trials involving this drug.8,11,18,19 In a 2017 trial,11 up to 13 imaging studies (preferably echocardiograms) were scheduled using the following protocol: at baseline, during treatment (at chemotherapy cycles 2, 6, 10, and 14) and during follow-up (months 3, 6, 12, 18, 24, 36, 48, 60), resulting in a potential total of 19,318 studies for 1,486 patients.

■ WHAT ACCOUNTS FOR DIFFERENT RESULTS BETWEEN TRIALS?

Several factors may help explain different event rates between clinical trials of the same drug.

Concomitant vs sequential therapy. In early studies, trastuzumab was given concomitantly with an anthracycline and cyclophosphamide. It has since been realized that cardiotoxicity rates are much lower if trastuzumab is given sequentially with other drugs. This is likely the most important explanation of the differences between the early and late anti-HER2 clinical trials.

More surveillance in the drug arm. A 2019 long-term study20 found a higher rate of cardiotoxicity in patients treated with trastuzumab than in those treated with chemotherapy alone. But LVEF was measured 5 times in the trastuzumab group vs no routine testing in the control group. Because cardiotoxicity is more likely to be revealed if more LVEF measurements are taken, more surveillance usually results in findings in the more tested arm.

Exclusion criteria. Cardiac event rates may be underestimated in clinical trials that exclude high-risk patients who are more likely to experience such events.

Problems of definition. Duplicative, inconsistent, and sometimes contradictory consensus criteria to classify cardiotoxicity can affect event rates. For example, a study participant experiencing an asymptomatic drop in LVEF from 60% to 35% might be reported as having either grade 0 left ventricular dysfunction, grade 1 heart failure, or a grade 3 ejection fraction decrease.21,22

■ PRINCIPLES OF CARDIAC SURVEILLANCE

Current recommendations are conservatively based on historical data

More than 50 years ago, Wilson24 wrote about the attributes of an ideal screening test and advised caution: “In theory, screening is admirable, but in practice there are snags; the central idea is simple and may appear deceptively straightforward.” Wilson’s screening criteria and their applications to surveillance echo-
cardiography during chemotherapy are presented in Table 2.24

**LVEF WITH ECHOCARDIOGRAPHY IS RECOMMENDED FOR SCREENING**

Currently, LVEF is the screening variable of choice.19 Strain assessment is a nonactionable supportive tool. However, it is the focus of ongoing research and is increasingly being used, especially as it received a formal Current Procedural Terminology code by the US Centers for Medicare and Medicaid for reimbursement to Medicare providers.25

Echocardiography is the preferred screening method, although cardiac magnetic resonance imaging is considered to be the gold standard and is advised in selected cases (ie, if echocardiographic images are inadequate or yield equivocal findings). Another option, multigated acquisition radionuclide scanning, is not a first-line test, as it involves radiation and introduces cross-modality error.

**BALANCING THERAPY RISKS AND BENEFITS**

The net benefit of therapy refers to balancing the risks of toxicity with prognosis and available treatment options. Potential cardiotoxicity may be more acceptable in the setting of a cancer with a poor prognosis and few treatment possibilities. On the other hand, cardiotoxicity is less likely to be an acceptable risk...
for a later-generation drug in a cancer with multiple existing therapies and a generally good prognosis.

Regarding breast cancer, regimens without an anthracycline have been shown to be as effective as those with an anthracycline, especially for women at low risk of recurrence. Strategies without an anthracycline involve much lower rates of cardiotoxicity, with rates of NYHA class III and IV heart failure being close, if not equal, to those with placebo (0.4% over 5 years or fewer than 1 per 1,000 patients per year). They have also demonstrated improved survival and favorable cardiac safety for metastatic cancer.

Because anti-HER2 treatment is used against a particularly aggressive cancer, decisions regarding interrupting or stopping it based on side effects have especially important implications. Whether such decisions should be made based on a surrogate echocardiographic end point, possibly in the absence of symptoms, needs careful consideration.

CARDIAC MANAGEMENT AND ANTI-HER2 THERAPY

Anti-HER2 treatment in patients with pre-existing cardiac dysfunction has been associated with a worse prognosis and higher rate of symptomatic heart failure compared with patients with preserved ejection fraction at baseline. However, preexisting cardiac dysfunction is a relative rather than an absolute contraindication to starting anti-HER2 treatment. The FDA recommends extreme caution in treating such patients, and a cardiologist should be involved in management.

For patients who develop clinically significant congestive heart failure, discontinuing anti-HER2 therapy should be strongly considered. For patients without symptoms, treatment-specific LVEF thresholds for stopping medications have been developed, with slightly different recommendations between FDA-approved labeling, clinical trial protocols, and professional society guidelines. Criteria from clinical trials that do not involve anthracycline therapy tend to be a little less stringent because anti-HER2-associated toxicity is considered to be dose-independent, nonapoptotic, and potentially reversible (type 2 cardiotoxicity). In contrast, anthracycline-mediated cardiotoxicity is regarded as type 1 (ie, irreversible and related to cumulative dose).

A commonly used threshold defining cardiotoxicity is a decrease in LVEF of more than 10% to a value below the lower limit of normal. Hussain et al, in a study of 23 patients with asymptomatic LVEF decline who continued trastuzumab, found that 14 patients (61%) tolerated it without a cardiac event, 6 (26%) developed further worsening of LVEF, 1 (4%) developed heart failure, and 2 (9%) died of a possible or probable cardiovascular cause.

Strategies to prevent or attenuate cardiotoxicities include participation in cardio-oncology programs (particularly for symptomatic or high-risk patients being considered for anti-HER2 treatment, including anyone with baseline low LVEF), early recognition of cardiac side effects, active cardiac surveillance, and cardioprotective medical therapy.

INTERPRETING SERIAL TESTING IS A CHALLENGE

Accurate diagnosis of cardiotoxicity is critical, as false-positive results may lead to inappropriate stopping of potentially lifesaving chemotherapy.

Serial echocardiography in patients with cancer can be difficult and measurement variability may be high. Reasons may be technical (eg, concomitant lung disease, high or low body mass, postoperative status) or involve confounding factors (eg, variable hemodynamics, medications, fluid status). Published test-retest variability data have generally been derived between 2 tests rather than multiple tests and conducted under optimized experimental settings in academic centers. Even optimized test-retest variability remains close to echocardiographic thresholds used to define real interval change representative of true cardiotoxicity, especially with multiple tests.

Outside of trial settings, false-positive results are not infrequent. In addition, pre-chemotherapy studies may manifest hyperdynamic function. Teasing out whether serial changes are related to cancer therapy vs comorbid illness (eg, concomitant arrhythmia, ischemia, stress cardiomyopathy, and myocarditis) may be challenging.
Optimizing measurement accuracy
Repeat echocardiographic studies should be performed in as consistent a manner as possible (eg, same equipment, technician, and reporting physician). Multiple ways to measure LVEF should be used, including quality 3-D echocardiography (ideally without contrast for highest reproducibility), the biplane Simpson method (with contrast, if necessary), and visual assessment, with reporting of the best available data.19 Global longitudinal strain may provide corroborative data when discordant; if discordant, the quality of the data should be reviewed again with particular attention to wall tracking. Ideally, differences between serial tests should be compared to the maximal detectable difference, a value that can be calculated for each echocardiographic laboratory, providing a threshold to distinguish likely test error from real change.31 For borderline cases, obtaining an experienced second opinion, an early interval repeat study, or an alternative test (eg, cardiac magnetic resonance imaging) should be considered.

Treating chemotherapy-related cardiomyopathy remains a challenge
Applying current guideline-directed heart failure management to chemotherapy-related cardiomyopathy can be particularly challenging. Especially for patients undergoing chemotherapy, titrating levels of beta-blockers and renin-angiotensin system antagonists to optimal dosing is often difficult because of poor tolerability. Outside these guidelines, data to support the use of cardioprotective medical therapy to prevent chemotherapy-related cardiotoxicity are modest at best. Studies are limited by marginal effect size, small patient numbers, and short follow-up.

Should general cardiotoxicity screening be eliminated?
Many have questioned the usefulness of currently proposed cardiac monitoring for patients on anti-HER2 therapy, particularly for those who are asymptomatic, without cardiovascular risk factors, and who have not had concomitant anthracycline therapy.32 Data assessing the cost-effectiveness of screening strategies for cardiotoxicity are limited.33 To avoid placing additional financial and time burdens on patients with cancer and their families, some have suggested that simply monitoring patients on clinical parameters alone is best.30

Current practice regarding screening for chemotherapy-related cardiomyopathy is a legacy of its mutable historical background. It is overshadowed by variable and conflicting guidelines, with the result that most patients on anti-HER2 treatment actually receive minimal or no cardiac imaging.34,35 If oncologists are voting with their feet, it appears that recommendations are perceived as promoting overtesting, with a common result being minimal or no testing in actual practice.

A PATH FORWARD
We suggest a more focused cardiac surveillance approach to low-risk, asymptomatic patients receiving anti-HER2 treatment. Routine serial LV EF measurement by echocardiography should be done only if patients have received anthracyclines or are considered to be at high risk (eg, concomitant hypertension, borderline low LV EF). For these patients, studies should be carried out at baseline, post-anthracycline (if appropriate), and every 3 months while on anti-HER2 treatment. Less frequent testing may be justified for patients with metastatic disease who have repeatedly normal LV EF test results. Patients should be informed about potential symptoms of cardiotoxicity and advised to report them promptly.

DISCLOSURES
The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer...

Address: Patrick Collier, MD, PhD, FASE, FESC, FACC, Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, J1-5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; colliep@ccf.org